1.3.2022 medac GmbH has decided to consolidate and strengthen its operations in the Nordic countries by creating one Nordic organisation.
15.2.2022 Nordic medac Urology Grant -apuraha oli haettavana ensimmäistä kertaa vuonna 2021. Pohjoismaisen 10 000 euron apurahan on saanut suomalainen lääketieteen tohtori Liina Salminen post doc -tutkimustyönsä tueksi. Salmisen tutkimusprojektissa selvitetään uusia tapoja virtsarakon syövän diagnosoimiseen ja hoidon tehon seurantaan.
Medac´s intention with this grant is to support Nordic resident physicians and/or specialists within urology with interest in research and development.
With immediate effect: 3 million proven antibody tests for SARS-CoV-2 and mastermix ready-to use PCR tests. 17 million more antibody tests available.
With immediate effect: medac´s proven methods for SARS-CoV-2 testing for the German-speaking world
At this moment in time, and after consultation of the competent authorities, we do not foresee any interruptions in production and therefore no supply shortages for our medicinal products because of the coronavirus COVID-19.
We support this by a prevention program and our purchasing and production strategy:
- medac has prepared itself carefully to protect employees and supply chain,
- medac operates its own production sites in Central Europe and the goods transport within Europe is not limited up to now,
- generally, medac has more than one supplier for the intermediate products used for its medicinal products,
- medac has sufficient stocks of all intermediate products so that supply fluctuations will not cause immediate shortages.
Medac’s marketing authorisation extension gives many patients with psoriasis access to guidelines-based MTX therapy for the first time.
Highly effective with reduced toxicity – Treosulfan-based regimen is a promising new conditioning therapy for MDS
Enhancing the potential of methotrexate.
Optimise rheumatism treatment in Finland with Metoject® PEN and ensure long-term success of therapy
Helsinki / Wedel (September 21, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the FIN-ERA cohort suggest that Finnish rheumatology exploits the potential of methotrexate as initial treatment and follows the European treatment guidelines in a slightly adopted way focusing on combination therapy: “At baseline, 68 % used methotrexate-based combination therapy, and 31 % used triple therapy with methotrexate, hydroxychloroquine, and sulphasalazine (the Fin-RACo regimen)”.
Methotrexate for psoriasis: effective, safe, favourable.
Medac with recent data on subcutaneous methotrexate from METOP study at the EADV in Geneva.
Geneva / Wedel (September 15, 2017). Methotrexate (MTX) is the most frequently used conventional systemic drug in the treatment of psoriasis. With over 50 years of successful experience in this setting, it is no wonder that recent treatment recommendations consider MTX as first-line and cost-effective therapeutic for the systemic treatment of psoriasis. And still the potential of MTX is often not fully exploited. In particular the dose and route of administration are aspects that should be considered.
Write personal the names of each living thing in the appropriate box.